Modality
mAb
MOA
Cl18.2
Target
GIP-R
Pathway
Proteasome
FSGSHS
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Mar 2026
Phase 1Current
NCT03526127
1,384 pts·HS
2020-06→2026-03·Active
1,384 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-192w agoInterim· HS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Active
Catalysts
Interim
2026-03-19 · 2w ago
HS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03526127 | Phase 1 | HS | Active | 1384 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R |